Essential hypertension is the main determinant of cardiovascular morbidity and mortality worldwide. During the last decades, several antihypertensive drug therapies have been introduced and tested in clinical trials, both as monotherapies and combination therapies. The current recommended therapeutic approaches effectively reduce the lifetime risk of experiencing major cardiovascular outcomes and disabling comorbidities, such as myocardial infarction, stroke, and congestive heart failure. On the basis of multiple proofs, antihypertensive therapy is currently recommended for improving event-free survival rate and quality of life in different clinical settings and conditions. At the same time, other cardiovascular drugs, including novel lipid-lowering, anti-platelet, and anti-coagulation agents, have been made available and also contribute to reduce the incidence of atherothrombotic diseases.

Legacy effect in the treatment of hypertension: persistent cardiovascular protection after conclusion of randomized clinical trials in hypertension / Gallo, G.; Battistoni, A.; Coluccia, R.; Tocci, G.; Volpe, M.. - In: CURRENT HYPERTENSION REPORTS. - ISSN 1522-6417. - 21:11(2019). [10.1007/s11906-019-0991-2]

Legacy effect in the treatment of hypertension: persistent cardiovascular protection after conclusion of randomized clinical trials in hypertension

Gallo G.;Battistoni A.;Coluccia R.;Tocci G.;Volpe M.
2019

Abstract

Essential hypertension is the main determinant of cardiovascular morbidity and mortality worldwide. During the last decades, several antihypertensive drug therapies have been introduced and tested in clinical trials, both as monotherapies and combination therapies. The current recommended therapeutic approaches effectively reduce the lifetime risk of experiencing major cardiovascular outcomes and disabling comorbidities, such as myocardial infarction, stroke, and congestive heart failure. On the basis of multiple proofs, antihypertensive therapy is currently recommended for improving event-free survival rate and quality of life in different clinical settings and conditions. At the same time, other cardiovascular drugs, including novel lipid-lowering, anti-platelet, and anti-coagulation agents, have been made available and also contribute to reduce the incidence of atherothrombotic diseases.
2019
cardiovascular prevention; hypertension; legacy effect; myocardial infarction; randomized clinical trials; stroke
01 Pubblicazione su rivista::01a Articolo in rivista
Legacy effect in the treatment of hypertension: persistent cardiovascular protection after conclusion of randomized clinical trials in hypertension / Gallo, G.; Battistoni, A.; Coluccia, R.; Tocci, G.; Volpe, M.. - In: CURRENT HYPERTENSION REPORTS. - ISSN 1522-6417. - 21:11(2019). [10.1007/s11906-019-0991-2]
File allegati a questo prodotto
File Dimensione Formato  
Gallo_Legacy-effect_2019.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 833.74 kB
Formato Adobe PDF
833.74 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1330456
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact